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Abstract 
Heat shock protein 90 (HSP90) is an important glucocorticoid receptor (GR) chaperone protein, and is supposed to 
be the key factor in regulating glucocorticoids (GCs) effects. The aim of the present study was to explore whether 
single nucleotide polymorphisms (SNPs) within HSP90AA1 gene affect the response of systemic lupus erythemato‑
sus (SLE) patients to GCs treatment. Two hundred and forty‑five SLE patients were treated with GCs (prednisone) for 
12 weeks. SLE disease activity index (SLEDAI) was used to assess the response of SLE patients to GCs treatment, and 
patients were classified into sensitive group and insensitive group. HapMap database and Haploview software were 
used to select tag SNPs. Tag SNPs were genotyped by using multiplex SNaPshot method. Univariate and multivari‑
ate logistic regression analyses were used to discriminate the impact of SNPs of HSP90AA1 gene on the response of 
SLE patients to GCs treatment. Two hundred and thirty three SLE patients finished the 12‑week follow‑up. Of these 
patients, 128 patients were included in sensitive group, and 105 patients were included in insensitive group. Seven 
tag SNPs were selected within HSP90AA1 gene. We detected significant associations for rs7160651 (dominant model: 
crude OR 0.514, 95 % CI 0.297–0.890, P = 0.018; adjusted OR 0.518, 95 % CI 0.293–0.916, P = 0.024), rs10873531 
(dominant model: crude OR 0.516, 95 % CI 0.305–0.876, P = 0.014; adjusted OR 0.522, 95 % CI 0.304–0.898, P = 0.019) 
and rs2298877 (dominant model: crude OR 0.543, 95 % CI 0.317–0.928, P = 0.026, adjusted OR 0.558, 95 % CI 0.323–
0.967, P = 0.037) polymorphisms, but not for other polymorphisms (P > 0.05). The present study demonstrates that 
HSP90AA1 gene SNPs may affect the response of SLE patients to GCs treatment.
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Background
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease characterized by multiorgan dysfunction 
including neural, cardiovascular, pulmonary, renal, mus-
culoskeletal and cutaneous systems (Rahman and Isen-
berg 2008; Chalayer et  al. 2014). The etiology of SLE is 
partially known, and multiple genetic and environmental 
factors are involved (Moser et  al. 2009). The ascertain-
ment of SLE prevalence and incidence faces difficulty, 
and the results of studies on prevalence (range from 20 to 
70 per 100,000 persons) and incidence (range from 1 to 
10 per 100,000 person-years) of SLE in the general pop-
ulation show marked differences (Borchers et  al. 2010; 
Pons-Estel et al. 2010). The number of patients with SLE 
exceeds 250,000 in the United States (Rahman and Isen-
berg 2008). In the past few decades, the life expectancy of 
SLE patients has improved from an approximate 4-year 
survival rate of 50  % to a 15-year survival rate of 80  % 
(Rahman and Isenberg 2008; Merrell and Shulman 1955; 
Abu-Shakra et al. 1995). However, SLE patients often suf-
fer long-term morbidity that can adversely affect their 
ability to work as well as quality of life (Pons-Estel et al. 
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2010). The direct and indirect costs of SLE are substantial 
among working-age adults, especially in female.
Glucocorticoids (GCs) are currently the mainstay of 
SLE therapy. Generally, the majority of patients with SLE 
respond favorably to GCs. However, a lot of evidence of 
wide interindividual differences in GC efficacy and toxic-
ity among patients have been observed (van Rossum and 
van den Akker 2011; De Iudicibus et al. 2011). The mech-
anisms by which interindividual differences develop are 
not yet fully understood. Genetic factors could, in part, 
explain the interindividual differences (Cronstein 2006). 
The effects of GCs are mediated through glucocorticoid 
receptor (GR), which, a transcription factor, binds steroid 
hormone ligands to affect the transcription of a number 
of target genes (Ito et al. 2006; Adcock et al. 1999). The 
transcriptional activity of GR is regulated by every step 
of its activation, including ligand binding, transcriptional 
cofactor binding, nuclear translocation, and DNA bind-
ing (Charmandari et  al. 2008; Silverman and Sternberg 
2008; Ouyang et al. 2012). Heat shock protein 90 (HSP90) 
is an important GR-related chaperone protein. It is sup-
posed to be the key factor in regulating GCs effects and is 
essential for activated GR translocation as well as trans-
activation (Grad and Picard 2007; Murphy 2005).
The HSP90AA1 gene is located on the long arm in 
human chromosome 14 and a number of single nucle-
otide polymorphisms (SNPs) of GR gene have been 
described (Chen et  al. 2005). Our previous study has 
showed that GR genetic variations may play a major 
role in the response of SLE patients to GCs treatment 
(Zou et  al. 2013b). However, to our knowledge, these is 
no study to explore the assciation bewteen HSP90AA1 
genetic polymorphisms and the response to GCs in 
patients with SLE. Therefore, in this study, we enrolled 
245 SLE patients treated with GCs (prednisone), and 
assessed the response of SLE patients to GCs treatment. 
HSP90AA1 gene SNPs were genotyped by using mul-
tiplex SNaPshot method. We explored whether SNPs 
within HSP90AA1 gene are related to the response of 
Chinese SLE patients to GCs treatment.
Results and discussion
Baseline characteristics of patients, genotype frequencies 
and results of Hardy–Weinberg equilibrium
Two hundred and thirty-three patients (95.10  %) com-
pleted the 12-week follow-up. Of these patients, 128 were 
classified as GCs-sensitive, while 105 patients were clas-
sified as GCs-insensitive, including twenty patients used 
other immunosuppressive agents because of lack of effi-
cacy. No significant difference was found in sex (male: 
7.03 vs 6.67  %), age (32.69  ±  11.27 vs 34.16  ±  11.09), 
body mass index (BMI) (20.76 ±  2.74 vs 21.17 ±  3.50), 
marital status (married: 72.66 vs 76.19 %), smoking (4.69 
vs 1.90 %), alcohol drinking (10.94 vs 14.29 %), baseline 
SLE disease activity index (SLEDAI) score (11.92 ± 1.91 
vs 11.50  ±  2.69) and GCs dose (45.55  ±  14.90 vs 
42.57  ±  17.06) between GCs-sensitive group and GCs-
insensitive group (Table  1, P  >  0.05). The genotype fre-
quencies of HSP90AA1 gene 7 tag SNPs were evaluated 
and were reported in Table 2. The genotype distributions 
of these SNPs were in Hardy–Weinberg equilibrium 
(P  >  0.05). Twelve patients failed to attend scheduled 
clinic visits. The clinical and demographic characteristics 
of the dropouts did not differ significantly from the com-
pleters (P > 0.05).
Association of HSP90AA1 gene polymorphisms 
with response of SLE patients to GCs
Univariate logistic analysis showed that the following 
three HSP90AA1 gene tag SNPs were significantly asso-
ciated with the response of SLE patients to GCs treat-
ment: rs7160651 (dominant model: OR 0.514, 95  % 
CI 0.297–0.890, P  =  0.018), rs10873531 (dominant 
model: OR 0.516, 95  % CI 0.305–0.876, P =  0.014) and 
rs2298877 (dominant model: OR 0.543, 95  % CI 0.317–
0.928, P = 0.026). In the multivariate regression analysis, 
the three SNPs were still significantly associated with the 
response of SLE patients to GCs treatment (rs7160651 
dominant model: OR 0.518, 95  % CI 0.293–0.916, 
P = 0.024; rs10873531 dominant model: OR 0.522, 95 % 
CI 0.304–0.898, P =  0.019; rs2298877 dominant model: 
OR 0.558, 95 % CI 0.323–0.967, P =  0.037). The results 
of univariate and multivariate logistic regression analyses 
are shown in Table 3.
In the present study, we evaluated the effects of SNPs 
within HSP90AA1 gene on the efficacy of GCs treatment 
for SLE patients. We observed significant associations of 
HSP90AA1 gene rs7160651, rs10873531 and rs2298877 
polymorphisms with GCs efficacy in Chinese patients 
with SLE. Our results demonstrate that HSP90AA1 gene 
polymorphisms may play a role in the response of SLE 
patients to GCs treatment.
GCs have well-known immunosuppressive effects and 
are one of the most widely used anti-inflammatory agents 
in SLE treatment. Despite the proven effectiveness and 
extensive use, interindividual differences in the response 
of SLE patients to GCs treatment have been reported, 
and some patients do not achieve complete remission, or 
else improve very slowly (van Rossum and van den Akker 
2011; De Iudicibus et  al. 2011). Meanwhile, the poten-
tial for many serious adverse events, including metabolic 
disease, osteoporosis and increased risk of cardiovas-
cular disease mar the clinical use of GCs (Saag 2002; de 
Vries et  al. 2007; Wang et  al. 2012). Patients, especially 
for those who respond poorly to GCs, are at high risk 
of adverse events. GCs cause their effects by binding to 
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GR, which is localized in the cytoplasm of target cells, 
and after binding the ligand, GR-ligand complexes are 
constructed and translocated into the nucleus (Ito et al. 
2006; Adcock et al. 1999). The function of GR is crucially 
dependent on interactions with HSP90 which facilitates 
GCs binding to the GR (Grad and Picard 2007; Murphy 
2005).
Similarities in the pathologies of cancer and autoim-
mune diseases, including SLE, have been noted for many 
years (Eck et al. 2009). HSP90 has been widely studied in 
cancer. New evidence continues to suggest that HSP90 
is overexpressed and associated with poor prognosis in 
many cancers. Wang et al. (2013) estimated the association 
of HSP90 expression with clinicopathological parameters, 
prognosis and the alteration of HSP90 expression after 
neoadjuvant chemotherapy in patients with advanced 
gastric cancer. The results showed that HSP90 expression 
was significantly associated with tumor site, tumor size, 
depth invasion, lymph node metastasis as well as clinical 
stages, and the patients with HSP90-positive had worse 
prognosis than those patients with HSP90-negative. Their 
study suggested that HSP90 plays an important role on 
tumor prognosis and may act as a promising target for 
prognostic prediction in gastric cancer. Tanaka et  al. 
(2013) characterized the efficacy of a potent HSP90 inhib-
itor NXD30001 against neurofibromatosis type 2 (NF2)-
related tumors in  vitro and in  vivo. Their study showed 
that HSP90 inhibition has significant antitumor activity 
against NF2-related tumor cells in vitro and in vivo, and 
provided certain evidence for the benefit of the HSP90 
inhibition against NF2-related tumors. Chu et  al. (2013) 
estimated the role of HSP90AA1 in ovarian cancer and 
their study suggested that HSP90AA1 is required for the 
proliferation and survival of SKOV3 cells. They found 
Table 1 Characteristics of of study patients
Characteristic Sensitive (n = 128) Insensitive (n = 105) Overall (n = 233) P value
Sex, No. (%) 0.913
 Male 9 (7.03) 7 (6.67) 16 (6.87)
 Female 119 (92.97) 98 (93.33) 217 (93.13)
Age, mean (SD) 32.69 (11.27) 34.16 (11.09) 33.35 (11.19) 0.318
BMI, mean (SD) 20.76 (2.74) 21.17 (3.50) 20.95 (3.10) 0.333
Marital status, No. (%) 0.539
 Unmarried 35 (27.34) 25 (23.81) 60 (27.75)
 Married 93 (72.66) 80 (76.19) 173 (74.25)
Smoking, No. (%) 0.246
 No 122 (95.31) 103 (98.10) 225 (96.57)
 Yes 6 (4.69) 2 (1.90) 8 (3.43)
Drinking, No. (%) 0.441
 No 114 (89.06) 90 (85.71) 204 (87.55)
 Yes 14 (10.94) 15 (14.29) 29 (12.45)
SLEDAI, mean (SD) 11.92 (1.91) 11.50 (2.69) 11.73 (2.30) 0.174
GCs dose mg/d, mean (SD) 45.55 (14.90) 42.57 (17.06) 44.21 (15.94) 0.157





















rs2298878 (A) 121 (94.53) 7 (5.47) 0 (0) 97 (92.38) 8 (7.62) 0 (0) 218 (93.56) 15 (6.44) 0 (0) 0.612
rs7157967 (C) 123 (96.09) 5 (3.91) 0 (0) 103 (98.10) 2 (1.90) 0 (0) 226 (97.00) 7 (3.00) 0 (0) 0.816
rs7160651 (A) 72 (56.25) 50 (39.06) 6 (4.69) 75 (71.43) 26 (24.76) 4 (3.81) 147 (63.09) 76 (32.62) 10 (4.29) 0.964
rs10873531 (G) 61 (47.66) 59 (46.09) 8 (6.25) 67 (63.81) 31 (29.52) 7 (6.67) 128 (54.94) 90 (38.63) 15 (6.43) 0.877
rs1190597 (G) 107 (83.59) 19 (14.85) 2 (1.56) 94 (89.53) 10 (9.52) 1 (0.95) 201 (86.26) 29 (12.45) 3 (1.29) 0.112
rs11547523 (G) 111 (86.72) 16 (12.50) 1 (0.78) 94 (89.52) 11 (10.48) 0 (0) 205 (87.98) 27 (11.59) 1 (0.43) 0.913
rs2298877 (T) 68 (53.13) 53 (41.41) 7 (5.46) 71 (67.62) 27 (25.71) 7 (6.67) 139 (59.66) 80 (34.33) 14 (6.01) 0.585
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that HSP90AA1 RNAi could inhibit the proliferation and 
increase the apoptosis of ovarian cancer SKOV3 cell line. 
They also found that high expression of HSP90AA1 could 
partially rescue the survival rate of SKOV3 cells which 
were treated with cisplatin and decrease the chemosensi-
tivity to cisplatin of SKOV3 cells. Recently, Coskunpinar 
et al. (2014) investigated HSP90AA1 gene polymorphisms 
in patients with non-small cell lung cancer (NSCLC). 
They found that the frequency of mutant genotypes for 
HSP90AA1 gene rs4947 polymorphism was significantly 
higher in the patient group than the frequency in con-
trols, indicating that HSP90AA1 gene polymorphisms 
may contribute to NSCLC development. In SLE patients, 
high expression of HSP90 has also been detected and cor-
related with increased levels of IL-6 as well as presence of 
autoantibodies to HSP90, suggesting that targeting HSP90 
may be an effective treatment for SLE (Shukla and Pitha 
2012; Hu et  al. 2006). In MRL/lpr mouse model of SLE, 
Shimp et  al. (2012) estimated if HSP90 inhibition would 
reduce disease, and their results suggested that HSP90 
may play a role in regulating T cell differentiation as well 
as activation and that inhibition of HSP90 may reduce 
inflammation in SLE. Moreover, a recent study has sug-
gested that the accumulation of HSP90 in the nucleus 
potentially hinders DNA-binding activity and transactiva-
tion, which may contribute to GCs resistance in patients 
with idiopathic nephrotic syndrome (INS) (Ouyang et al. 
2012). The above evidence appears to support our res-
luts. Since HSP90 protein expression may have an impact 
on cellular sensitivity to systemic GCs treatment, SNPs 
within HSP90AA1 gene may contribute to decreased/
increased GC responsiveness. However, these is no other 
study to explore the association of HSP90AA1 gene pol-
ymorphisms with the response of SLE patients to GCs 
treatment. Further studies are still needed to assess the 
current results. The association may result from the direct 
effect of these polymorphisms themselves, or through 
linkage disequilibrium with another functional polymor-
phisms in the structural or regulatory regions of the gene. 
Further studies of the function of these polymorphisms 
are needed.
The sample size of the current study is limited. Twelve 
patients dropped out of the study. Additionally, the use 
of hydroxychloroquine, considered as a second-line treat-
ment in SLE patients, offers a wide range of benefits 
(Costedoat-Chalumeau et  al. 2010; Chen et  al. 2015). 
Thus, patients also received hydroxychloroquine therapy 
in the study. These limitations may have certain impact 
on our results.
Conclusion
In conclusion, this is the first study to explore the asso-
ciation of the response to GCs with HSP90AA1 genetic 
polymorphisms in SLE patients. The present study dem-
onstrates that HSP90AA1 gene rs7160651, rs10873531 
and rs2298877 polymorphisms may affect the response 
of SLE patients to GCs treatment. Larger studies are 
required to further assess the association. Meanwhile, 




In order to interpert genetic and environmental influence 
on individualized response to treatment in SLE patients, 
a pharmacogenetic study was conducted in Anhui Medi-
cal University. This study was carried out as part of the 
pharmacogenetic study. A total of 245 patients, enrolled 
in the First Affiliated Hospital and the Second Affiliated 
Hospital of Anhui Medical University (Anhui, China), 
were included in the study. All patients were of unrelated 
Han Chinese ancestry, and met the revised criteria for 
the classification of SLE established by the American Col-
lege of Rheumatology (ACR) in 1997 (Hochberg 1997). 
These patients have the SLEDAI score of 5 or higher, 
and no patients had recent exposure to GCs (in the last 
three months). Potential patients were excluded if they: 
(1) had lupus crisis or required GCs plus therapy; (2) had 
systemic fungal or bacterial infection; (3) were pregnant 
or lactating women; (4) were allergic to hydroxychloro-
quine. The treatment and efficacy assessment used for 
the present study has been described in our previous 
study (Zou et al. 2013a, b). Briefly, patients were treated 
with GCs (prednisone) combined with hydroxychlo-
roquine (400  mg/day) for 12  weeks. At the start of the 
study, prednisone 10 mg/day–0.5 mg/kg/day was admin-
istrated to the patients whose SLEDAI scores were <10, 
and 0.5–1  mg/kg/day was administrated to the patients 
whose SLEDAI scores were ≥10. The dosage adjustments 
were made through the consultation from the rheumatol-
ogists during the course of treatment. SLEDAI was used 
to assess the response of SLE patients to GCs treatment 
at weeks 0, 4, 8 and 12. The GCs-sensitive was defined 
as a 4 points or less in the SLEDAI score at the 12 weeks. 
The GCs-insensitive was defined as a 5 points or greater 
in the SLEDAI score at the 12  weeks, and patients who 
took other immunosuppressive agents because of lack of 
efficacy in the course of treatment were also considered 
as GCs-insensitive. The ethical committee of Anhui Med-
ical University approved the study. We obtained written 
informed consent from all patients and fully explained 
the procedures of the study.
Tag SNP selection and genotyping
HapMap database and Haploview software were used 
to select tag SNPs. SNPs within HSP90AA1 gene were 
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retrieved from HapMap database (Chinese Han in Bei-
jing) sample (release No. 24/phaseII Nov08, on NCBI 
B36 assembly). r2 threshold of 0.8 and minor allele fre-
quency (MAF) threshold of 0.01 were used as cut-off 
for tag SNPs selection, and, finally, 7 tag SNPs were 
selected: rs2298878, rs7157967, rs7160651, rs10873531, 
rs1190597, rs11547523 and rs2298877. Venous blood 
was obtained by venepuncture from each subject. We 
extracted DNA from the peripheral blood by using a 
blood extraction kit (QIAGEN, Germany), and stored 
DNA at –80  °C until use. Genotyping of tag SNPs in 
HSP90AA1 gene was performed by multiplex SNaPshot 
technology using an ABI fluorescence-based assay allelic 
discrimination method (Applied Biosystems, Foster city, 
CA).
Statistical analysis
Mean and standard deviation (SD) of continuous vari-
ables, and proportions of categorical variables are 
presented as descriptive statistics. Differences for con-
tinuous variables were tested by using t-test. Chi square 
test was used to test differences for categorical variables 
and Hardy–Weinberg equilibrium. Dominant and reces-
sive models were applied for the analysis of genotype dis-
tribution. Univariate and multivariate logistic regression 
analyses were used to discriminate the impact of SNPs 
of HSP90AA1 gene on the response of SLE patients to 
GCs treatment (GCs-sensitive 0, GCs-insensitive 1). We 
used multivariate logistic regression to adjust for poten-
tial confounding factors (sex, age, BMI, marital status, 
smoking status, alcohol drinking, baseline SLEDAI score 
and GCs dose (mg/day)). All statistical analyses were per-
formed using SPSS software version 10.01 (SPSS, Inc, 
Chicago, IL). Within this report, P  <  0.05 were consid-
ered statistically significant.
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